First AD

Second AD

Looking Ahead in SCLC: ADCs and Other Novel Agents

Video content above is prompted by the following:

What is your perspective on the emerging data for ADCs in this space? Where might these fit into the evolving treatment paradigm, and how would you sequence them with other available therapies?

Dowlati A, et al. WCLC 2024. Abs OA04.04 

What are your thoughts on current strategies and emerging data surrounding T-cell engagers, and how might they impact the treatment landscape?

What evidence supports MRI surveillance as an alternative to PCI for brain metastasis management in ES-SCLC? What factors might still warrant PCI?

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025

OncLive Insights

Panelists discuss how emerging antibody-drug conjugate (ADC) data from TROPiCS-03 and IDeate-Lung01 suggest potential in extensive-stage small cell lung cancer (ES-SCLC), impacting sequencing with current therapies. T-cell engagers like BI 764532 and HPN328 may reshape treatment. MRI surveillance, per retrospective data and MAVERICK, offers an alternative to prophylactic cranial irradiation (PCI), though select factors may still justify PCI use.